SiRNA against lncRNAs (LOC100129516 siRNA1, LOC100129516 siRNA2, LOC100129516 siRNA3; lnc-KCNC3-3:1 siRNA1, lnc-KCNC3-3:1 siRNA2, lnc-KCNC3-3:1 siRNA3; ENSG00000261482.1 siRNA1, ENSG00000261482.1 siRNA2, ENSG00000261482.1 siRNA3; siRNA-ctrl) were purchased from RiboBio (Guangzhou, China).
LOC100129516 siRNA1, LOC100129516 siRNA2, LOC100129516 siRNA3; lnc-KCNC3-3:1 siRNA1, lnc-KCNC3-3:1 siRNA2, lnc-KCNC3-3:1 siRNA3; ENSG00000261482.1 siRNA1, ENSG00000261482.1 siRNA2, ENSG00000261482.1 siRNA3 or siRNA-ctrl was transfected into HUVEC cells using Lipofectamine® 2000 (Thermo Fisher Scientific, Waltham, MA, USA).
The sequences of siRNAs were presented as following: LOC100129516 siRNA1, 5′-CCCAGGCTACCATCCCTCCAAATAA-3′; LOC100129516 siRNA2, 5′-CACCATTCACTTTCCGGCAGCTTAG-3′; LOC100129516 siRNA3, 5′-CCGCTCCTTCTTGTCAGAGTAAGTA-3′; siRNA-ctrl, 5′-CCCATCGTACCTCCCAACCAGATAA-3′; lnc-KCNC3-3:1 siRNA1, 5′-ACAACATGCGTGGGAGGCGACAGGT-3′; lnc-KCNC3-3:1 siRNA2, 5′-ACAGGTCGCGACGGCAGCCACAGGT-3′; lnc-KCNC3-3:1 siRNA3, 5′-GAGGCTCCCTGAACCACCCTCCCTC-3′; siRNA-ctrl, 5′-ACACGTAGGTGGGAGCAGCACAGGT-3′; ENSG00000261482.1 siRNA1, 5′-TGGCTGCTGGAGAGGATTCTCACAA-3′; ENSG00000261482.1 siRNA2, 5′-GGCTGCTGGAGAGGATTCTCACAAA-3′; ENSG00000261482.1 siRNA3, 5′-GCTGCTGGAGAGGATTCTCACAAAG-3′; siRNA-ctrl, 5′-GCTGCTGTCAAGGATTCTGGAGCAA-3′.
Sun L., He X., Zhang T., Tao G, & Wang X. (2021). Knockdown of lnc-KCNC3-3:1 Alleviates the Development of Atherosclerosis via Downregulation of JAK1/STAT3 Signaling Pathway. Frontiers in Cardiovascular Medicine, 8, 701058.
+ Open protocol